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INTRODUCTION: Acute Severe Ulcerative Colitis (ASUC) is a life threatening condition 
which requires urgent and aggressive medical therapy to reduce mortality, morbidity and 
avoid surgery; the mainstay of treatment is intravenous corticosteroids. To facilitate this 
process it is essential to identify patients at high risk of poor outcomes and emergency 
colectomy. Numerous risk factors predicting the need for surgery have described in the 
Western literature both at presentation and on day 3 of intravenous therapy, however there 
are no local data addressing this issue. As such it is unclear if these predictors are applicable 
in our setting. The aim of this study is thus to identify risk factors for emergency colectomy 
in patients admitted to Groote Schuur Hospital with ASUC. 
METHODS: A retrospective cohort study of 98 patients admitted with ASUC between 
January 2003 and January 2013 was performed. Clinical, demographic, laboratory, 
radiological and endoscopic factors on admission and 3 days thereafter were analysed as 
predictors of colectomy by univariate and multivariate analysis. Patients were followed up 
retrospectively for 90 days 
RESULTS: Twenty five percent of the cohort underwent emergency colectomy, 80% within 
15 days of presentation. On univariate analysis factors on admission which predicted 
colectomy were exposure to oral corticosteroids (p=0.01), megacolon (p=0.049) or mucosal 
islands (p=0.04) on abdominal Xray, and a short duration from UC diagnosis until 
presentation with ASUC (p=0.04). There was no significant association between ethnicity, 
age at UC diagnosis, gender, family history of IBD, or smoking status. There was also no 
association with baseline haemoglobin or CRP. The only day 3 variable that significantly 
predicted colectomy was serum albumin (p=0.01).This was also the only variable to remain 
significant on multivariate analysis (OR 0.79, 95% CI 0.65-0.97, p=0.01).  
CONCLUSION: ASUC is a medical emergency, predicting which patients will likely require 
colectomy is a very valuable tool in guiding therapeutic management. In our study the only 
variable significantly associated with colectomy was hypoalbuminaemia on day 3. However 
given the small study numbers a larger prospective study would be of value in identifying 




BACKGROUND AND LITERATURE REVIEW 
Iidiopathic inflammatory bowel disease (IBD) comprises by and large two types of intestinal 
disorders, Crohns disease (CD) and ulcerative colitis (UC); both are characterized by chronic 
gastrointestinal inflammation. Their clinical course is marked by acute exacerbations and 
periods of remission. The exact etiology remains unknown, but accumulating evidence 
suggests that IBD is the result of complex interactions between the genetic makeup of the 
individual together with environmental factors, mucosal immunity and the gut microbiome 
(Gulliford et al. 2011). 
Ulcerative colitis is characterized by continuous, superficial inflammation that is limited to 
the colon with no upper gastrointestinal or small bowel involvement. One exception is black 
wash ileitis seen in less than 10 percent of cases, almost always in patients with pan colitis 
(Satsangi at al. 2006) UC is classified using the Montreal classification (Appendix 1) 
according to the extent of involvement of the colon; 40 % have proctitis (limited to the 
rectum), 40 % limited disease (affecting the left side of the colon up to the splenic flexure), 
and 20 % pan colitis (involving the whole colon).  Most flare ups of UC are mild to moderate 
in severity, however approximately 15% of patients will have an episode of acute severe UC 
(ASUC) in their lifetime, and for about 20 % this will be their first presentation. 
 
 ASUC is a medical emergency as it can be complicated by toxic megacolon and perforation. 
ASUC is usually diagnosed using True love and Witt’s criteria which have been widely 
adopted by international bodies and is defined by the passage of six or more bloody stools per 
day together with any one of an additional 4 criteria: a tachycardia (>90 bpm), body 
temperature > 37.5ºC, anaemia (hemoglobin <10.5 g/dl), or an elevated erythrocyte 
sedimentation rate (ESR) or C-reactive protein (CRP) >30 mm/h) (Travis at el.2011). 
Untreated ASUC has high mortality rates; ranging between 22 and 75 % and is therefore 
regarded as a medical emergency requiring aggressive medical and surgical therapy. The 
management of ASUC requires a multi-disciplinary approach which includes a 
Gastroenterologist, Colorectal surgeon, Clinical radiologist, Psychologist and stoma therapy 
expert. Initial evaluation includes a plain chest X-ray to exclude air under the diaphragm 
which is a sign of intestinal perforation as well as to rule out active tuberculosis. Erect and 
supine abdominal X-rays are also essential in the work up of a patient with ASUC to look for 
signs of severity which include colonic dilation, toxic megacolon (transverse colon diameter 
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of more than 5.5 cm), ahaustral appearance, thumb printing, mucosal islands and dilated 
small bowel (suggesting an ileus). Abdominal X-ray may also be helpful in estimating the 
extent of colitis (Travis et al. 2010). The second European evidence based consensus on the 
diagnosis and management of UC recommends that laboratory investigations include 
electrolytes, full blood count, liver function testing and CRP (Dignass et al.2012). It is 
important to exclude other causes of diarrhea and bleeding, therefore a stool examination for 
microscopy, culture and Clostridium difficile toxin analysis is imperative. Infective colitis 
should be excluded in all patients, but especially those with abrupt onset of diarrhea, 
vomiting or fever and those with a recent history of foreign travel (Gulliford et al. 2011). 
Endoscopic imaging of these patients involves use of rigid or flexible sigmoidoscopy (which 
is preferable) and biopsies to confirm the diagnosis of UC macroscopically and 
histologically. Biopsies are also taken to rule out concurrent cytomegalovirus (CMV) which 
often complicates ASUC. Normal rectal mucosa is uncommon in active UC and an 
alternative diagnosis such as CD colitis, infective colitis or ischemic colitis should be 
entertained.  
 
The clock starts ticking the moment a patient with ASUC is hospitalized and urgent 
investigation and treatment is key. In ASUC there is often progression of inflammation 
beyond the mucosa, with associated systemic toxicity. These patients are at risk of 
developing toxic megacolon and perforation with high mortality and morbidity. To optimize 
the management of ASUC, meticulous attention should be given to confirming the diagnosis, 
establishing disease activity, excluding complications and initiating appropriate treatment. 
These very ill patients also require close monitoring by a multidisciplinary team. The 
mainstay of therapy is early and aggressive intravenous corticosteroids (Gulliford et al. 
2011).  
 
At presentation the severity of the UC flare and the risk of colectomy can be predicted. The 
number of positive True love and Witt’s present criteria at presentation can be used as an 
index for predicting colectomy and correlate well with disease severity. In patients with 6 or 
more bloody stools per day plus 1 additional criterion 9% will undergo surgery, with 2 
additional criteria 31% and 3 additional criteria 48% (Dinesen, 2010). Other predictors of 
colectomy at diagnosis include mucosal islands, colonic dilatation on abdominal X-ray (75%) 




Approximately 60% of patients will respond rapidly to IVI corticosteroids; however the 
remainder fail to improve. It is important to identify these steroid failures early as there is a 
narrow window of opportunity to salvage the colon. Two treatment options can be used as 
rescue therapy in these people, cyclosporine and the anti-TNFα biologic infliximab (Croft et 
al, 2013). These 2 treatment options appear to be of equal efficacy. In order to avoid 
colectomy these agents need to be give early in the course of the disease. The Oxford Index 
severity scoring criteria on day three of intravenous corticosteroids is widely used to identify 
these steroid refractory patients. People fulfilling these criteria (8 or more stools per day or 3 
to 7 stools per day plus a CRP >45) are regarded as having failed steroid therapy and 85 % 
will end up with a colectomy on that particular admission (Travis et al. 1996).These criteria 
are used in our institution to guide therapeutic decision making and help to decide whether 
early salvage therapy is indicated. Delayed colectomy following prolonged medical therapy 
(>8 days) leads to increased post-op complications (Leonard-Jones et al.1975). A 2-fold 
increases in in-hospital mortality has been described if colectomy is performed after 6 days 
(Kaplan et al. 2008). 
 
In conclusion the management of ASUC remains a challenge and clear identification of 
parameters that can identify patients at high risk of colectomy will facilitate the initiation of 
early and aggressive therapy within a multidisciplinary team. In addition timely colectomy in 
those who fail to respond will reduce surgical mortality and morbidity. 
 
STUDY RATIONALE 
Multiple indices have been used to predict colectomy in patients diagnosed with ASUC, 
mostly in Western cohorts. There is currently no local data on whether these variables are of 
value in our population. Our Institution manages most state patients with UC in the Western 
Cape and as such we are an ideal study site to address this research question. Limited 
resources, notably the availability of infliximab as colon salvage therapy, can be then 
optimized based on local evidence. Genetic, environmental and social factors in our 
population are different from other parts of the developed world and it is unclear if predictors 
evaluated in these populations are generalizable in our setting. 
 
STUDY AIM 
To analyze clinical, radiological, laboratory and endoscopic parameters at the time of 
admission, as well as on day 3 of admission, in patients with ASUC in order to establish 
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1) To identify factors predicting colectomy in patients with confirmed ASUC on day 0 and day 
3 of admission. 
2) To evaluate the Oxford criteria on day 3 of treatment and review its validity in our setting. 
 
STUDY METHODS 
Study design  
A retrospective study of patients admitted to Groote Schuur Hospital with ASUC between the 
1st January 2003 and. 1st January 2013. Patients will be identified from inpatient admission 
records, surgical files, as well as our established IBD database  
 
DATA COLLECTION 
Case folders of all patients admitted with ASUC (GSH medical, surgical wards and 
ICU) during the study period will be evaluated and appropriate data extracted and  
entered into an Excel database. The following information will be collected: 
 Demographic data: name, folder number, date of birth, age at diagnosis and on admission, 
gender, race, date of UC diagnosis, family history of IBD, date of ASUC diagnosis, smoking 
history, first time presentation or previously diagnosed, number  of previous attacks of 
ASUC. 
 Clinical factors on day 1 and day 3: number of stools per day, temperature, heart rate, 
hemoglobin, ESR, CRP, albumin, stool MC&S and C difficile toxin. 
 Radiological findings on day 1: Chest X-ray, Abdominal X-ray findings. 
 Medicine use on admission: 5-ASA, topical steroids, oral corticosteroids, azathioprine, TNF 
alpha blockers. 
 Endoscopy features on admission: grade of colitis, deep ulcers, CMV.  
 Medical management during admission: antibiotics, high dose IVI steroids,    cyclosporine, 
infliximab. 
 Surgical management: colectomy date, indication for colectomy (toxic megacolon, 
perforation, severe bleeding, failure of medical therapy, ongoing active UC)  
11 
 
 Surgical outcomes: perioperative morbidity and mortality, surgical complication up to 90 
days post discharge 
 Mortality rates. During admission and up to 90 Days post discharge 
 
STATISTICAL ANALYSIS 
The association between all baseline risk factors as well as those on day 3 of admission and 
the risk of colectomy will be assessed by univariate analysis. The distribution of all 
continuous variables will be evaluated and expressed as medians and interquartile ranges 
(IQR) or means ± standard deviations (SD) as appropriate. Statistical analysis will employ 
Chi2, Fishers exact, Student t test, Wilcoxon rank sum test or Kruskal-Wallis testing as 
appropriate. Those variables with P values less than 0.10 will be further tested in a series of 
logistic multivariate regression models. The analysis will be performed using STATA version 




 All patients with a confirmed diagnosis of ASUC using True love and Witt’s criteria will be 
included in the study. 
EXCLUSION CRITERIA 
 Patients with incomplete data on admission for the inclusion criteria will excluded. 
 Patients with a revised diagnosis at a later stage (within 90 days).  
 
ETHICAL CONSIDERATIONs 
Ethical considerations as per the local Ethics committee will be adhered to so as to limit harm 
and breach of patient confidentiality. Only the principal investigator and his  immediate 
coworkers will have access to the identity of the study participants and their personal details. 
Names, hospital folder numbers or any other information which may allow identification of 
the subjects involved in the study will not be divulged to any other person or appear in the 
dissertation or any subsequent publication. Ethical approval from the local Ethics Committee 
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INTRODUCTION AND BACKGROUND 
Idiopathic inflammatory bowel disease (IBD) is represented by and large by two types of 
intestinal disorders, Crohn’s disease (CD) and ulcerative colitis (UC). Microscopic colitis, 
primary collagenous colitis, lymphocytic colitis and IBD- unclassified (IBD-U) are less 
common, but increasingly recognized. UC and CD  are characterized by chronic relapsing-
remitting immune activated gastrointestinal inflammation (Satsangi et al. 2006). CD is 
characterized by transmural segmental inflammatory involvement with either fistulising or 
stenotic phenotypes and can affect any part of the gastrointestinal tract, although the terminal 
ileum and caecum are predominantly affected. UC is characterised by continuous ascending 
mucosal inflammation exclusively involving the colon, with the rare exception of backwash 
ileitis (Haskell et al. 2005). IBD is currently classified using the Montreal classification 
system (Satsangi et al. 2006). CD is classified according to age at diagnosis, disease location 
and disease behaviour. UC is classified according to the extent of colonic involvement, and 
the severity of disease (Tables 1 - 3). UC is the most common form of IBD and was first 
described in the 1800s, whereas CD was first reported in 1932 as “regional ileitis”(Crohn et 
al. 1932).IBD has a variable clinical course with periods of quiescence and episodes of active 
disease where symptoms worsen. Most IBD flares are managed as outpatients. Severe flares 
are usually managed as inpatients as they require aggressive medical therapy and may also 
require surgery. This literature review describes the epidemiology, aetiology, pathogenesis 
and natural history of UC, with a focus on acute severe ulcerative colitis (ASUC). The 
diagnosis of ASUC, assessment of severity, medical therapy including rescue therapy and the 
decision regarding the need and timing of surgery will be discussed. 
 
EPIDEMIOLOGY OF UC 
The incidence of UC has plateaued or even decreased  (Molinie et al. 2004; Lakatos et 
al.2004) in developed countries of North America and Western Europe, while there is a rising 
trend in developing countries (Lakatos et al. 2004). The incidence of UC varies from 0.5 to 
31.5 per 100 000 people per annum , depending on the studied population  (Burisch et al 
2013).  The prevalence is lower in developing countries ranging from 5.3 to 63.6 per 100 000 
people in Asian populations  (Asakura et al. 2009). The disease typically follows a relapsing–
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remitting course and usually presents with a bimodal pattern of incidence with a predominant 
peak between the ages of 15 and 30 years, and a second smaller peak between ages 50 and 70 
years (Loftus et al. 2002). In recent studies, the majority of patients with UC were between 
30-40 years at diagnosis (Burisch et al. 2013). UC was previously considered  rare in 
children, but recent studies from different countries have demonstrated an increase in 
paediatric and adolescent populations  (Pant et al. 2013) . Henderson et al showed an 
increased incidence in children less than 16 years of age when comparing periods 1990 – 
1995 to 2003 – 2008, with incidence rates of 1.59 to 2.06/100 000 per year respectively 
(Henderson et al. 2012). The incidence of ulcerative colitis is higher in developed countries 
(Northern Europe and USA) than in developing countries, and in urban versus rural areas. 
Lowest rates of incidence and prevalence have been described in Eastern and Southern 
countries, with increasing numbers recorded in those countries that have adopted a western 
lifestyle (da Silva et al. 2014). North America and northern Europe have the highest 
incidence and prevalence rates of ulcerative colitis, with incidence rates varying from 9 - 20 
cases per 100 000 person-years, and prevalence rates from 156 - 291 cases per 100 000 
(Ordás et al. 2012). Bernstein showed that there is a slight predominance of males affected by 
UC as compared to females (Bernstein et al. 2006). Loftus however showed no gender 
difference  in UC incidence (Loftus et al. 2002). Cigarette smoking (in particular current 
smokers) has a protective effect for UC (Mahid et al. 2006). Former or non-smokers have an 
increased risk of acquiring UC  with higher rates of hospital admission and colectomy 
(Beaugerie et al. 2001; Birrenbach et al. 2004). 
First-degree relatives have a 5.7 – 15.5 % risk of developing UC. Henriksen et al in their 
prospective study described a 10.1% incidence of a family history of IBD among 454 
individuals with UC (Henriksen et al. 2006). 
There is some published data on the demographics of IBD in South Africa. In a 1986 Cape 
Town IBD cohort Wright et al showed that only 30% of 197 UC patients were either coloured 
or black. There was an increase in the incidence of UC between 1970 and1977 and again 
between 1980 and 1984. The age distribution of patients presenting for the first time ranged 
between 20 to 40 years (Wright JP at al 1986). These racial demographic appear to have 
changed dramatically over the past 30 years. Data from the newly instituted South African 
IBD Registry (personal communication – Dr David Epstein) has shown that there remains a 
Caucasian predominance (39.6%), but this is now closely followed by coloured (39%), then 
Asian (7.3%) and black (5.6%) populations. This increase in incidence in non-Caucasians 
may reflect changes in environmental risk factors. Chu et al in their study of 370 patients (63 
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were UC, 88 were CD patients and 219 were controls) in the Western cape of South Africa, 
described a protective relationship of childhood Helminth exposure against development of 
IBD. They showed in multivariate analysis that, helminth infection as well as mixed race, 
smoking and shared housing were protective against developing UC(Chu et al. 2013). 
Environmental and host genetic factors play a role in UC pathogenesis. 
 
AETIOLOGY AND PATHOGENESIS OF UC 
UC is a complex and multifactorial disease, of which the exact aetiology remains uncertain. 
Current evidence suggests that UC results from an inappropriate inflammatory response to 
intestinal microbes in a genetically susceptible host. The triggering event remains unclear 
although a genetic predisposition as well as environmental factors appears to be of 
importance.  Multiple potential pathways have been studied, mostly in animal models, and 
UC is thought to stem from dysregulated microbial handling by the gut, epithelial barrier 
damage and aberrant immunological responses. (Dixon et al. 2015). 
Defective goblet and paneth cell function has been described, resulting in abnormalities in the 
mucous layer, intercellular tight junctions and cellular adhesion molecules. Ultimately the 
epithelial barrier is impaired which increases permeability and antigenic uptake (Ordás I et 
al.2012), Antigen presenting cells (APCs) are activated through pattern recognition receptors 
as well as by these antigens directly as they penetrate the epithelial barrier and lamina 
propria. Stimulation of NF-kβ pathways in the APCs leads to the transcription of pro-
inflammatory cytokines, notably Tumor Necrosis Factor alpha (TNF α), Interleukin-12 (IL-
12), IL-6, IL-23, IL-1β. The release of these cytokines further stimulates APCs to activate 
naïve CD4 T-cells (Th0 cells) and promote their differentiation into effector Th2 cells, which 
produce additional inflammatory cytokines such as IL 4. Regulator and effector T cell 
homeostasis is disturbed in UC and this leads to atypical Th2 responses mediated by non-
classical natural killer T cells (NKT) which produce interleukin IL 13 and IL 5 (Zenewicz et 
al. 2010). IL 13 exerts cytotoxic effects against epithelial cells, promotes apoptosis and alters 
the structure of proteins forming tight junctions in the epithelial layer. The resultant 
inflammatory response (through expression of mucosal addressin-cell adhesion molecule 1 on 
endothelial cells) attracts circulating T cells bearing integrin-α4β7 to the gastrointestinal 
microvasculature. These then adhere to colonic endothelial cells allowing them to diapadese 
into areas of colonic inflammation. This upregulated response leads to the release of specific 
chemokines such as CXC L1, CXC L3 and CXC L8 by humoral cells, and thereby potentiates 
the recruitment of polymorphonuclear cells resulting in perpetuation of inflammation and a 
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systemic inflammatory response. This vicious cycle driven by pathogen activated APCs, 
defective tight junctions, increased permeability, and activation of a dysregulated immune 
response ultimately leads to epithelial breakdown, ulcer formation, bloody diarrhoea, 
abdominal pain and systemic signs of inflammation.  
THE DIAGNOSIS AND NATURAL HISTORY OF UC 
The diagnosis of ulcerative colitis is based on clinical symptoms as well as typical 
endoscopic and histological features. The differential diagnosis includes infective causes 
(especially Clostridium difficle, shigellosis, amoebiasis, haemorrhagic E coli, typhoid species 
and cytomegalovirus infection in immunosuppressed patients). These need to be ruled out 
before a diagnosis can be made. With a few exceptions, UC always involves the rectum with 
varying degrees of proximal extension. It is confined to the colon, although infrequently UC 
may involve the terminal ileum and is called backwash ileitis. UC is classified by the 
Montreal classification (Appendix 1) according to the extent of colonic involvement as 
proctitis (30-50%), left-sided colitis (20-30%) or extensive colitis (20%) (Satsangi et al. 
2006). Disease extent can progress with time in 25-50% of patients to involve more proximal 
colon. The severity of UC is also classified by the Montreal classification (Appendix 1)  
The majority of UC patients present with mild-moderate disease (S1-S2), however 25% will 
have severe disease (S3) at diagnosis. Additionally, over the course of their lifetime, 15% of 
affected patients will develop an acute severe flare requiring hospitalisation (Van Assche et 
al. 2011). Dinesen et al described a cohort of 186 patients admitted with ASUC for intensive 
treatment. The first attack occurred at presentation in 34%, within 1 year of diagnosis in 24% 
(cumulative total 54%), and 18% within 1 to 5 years of diagnosis. Twenty eight percent 
presented with ASUC for the first time more than 5 years after diagnosis. Patients who are 
diagnosed at a young age (15–30 years), and those with concurrent primary sclerosing 
cholangitis, are more likely to have extensive disease at presentation than those without these 
risk factors (Dinesen et al. 2010). Disease flares that are associated with progression of 
anatomic extent ( from proctitis to left-sided colitis or extensive colitis) usually follow a more 
severe course and require more intensive medical treatment (Etchevers et al. 2009) than those 
who’s UC does not progress. The anatomical extent of mucosal inflammation is clearly one 
of the most important factors determining disease course. Patients with more severe disease 
tend to have more extensive forms of UC (pancolitis) than do those with less severe disease. 
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Despite the often severe disease manifestations, patients with ulcerative colitis do not have an 
increased mortality risk compared with the general population (Selinger et al. 2013) . 
The long term natural history and  clinical behaviour pattern of UC is best described in the 
IBSEN study, which followed a large population based IBD cohort (including  519 UC 
patients) over a10 year period. Four distinct patterns of UC symptom behaviour were 
described. The majority of patients (55%) had significant intestinal symptoms in the first year 
after diagnosis, followed by symptoms suggesting remission or mild disease. Thirty seven 
percent of UC patients described chronic intermittent symptoms, while 22% had chronic 
continuous symptoms. Only 1%  described an increase in symptom severity following an in 
initial mild presentation  (Solberg et al. 2009). 
 
ASSESSING THE SEVERITY OF UC AT PRESENTATION 
Acute severe ulcerative colitis  is characterised by  bloody diarrhoea of six or more stools per 
day with one or more additional systemic signs (Heart rate >90 /min, Temperature > 37.8 ℃, 
Haemoglobin <10.5 g/dL and C-reactive protein (CRP) or Erythrocyte sediment rate > 30) as 
initially described by True Love and Witts  (Truelove & Witts 1955; Dignass et al. 2012). 
These criteria are aligned with the more recent Montreal classification of UC severity 
(Appendix 1). Less than 10% of UC patients with ASUC will present at diagnosis  
(Langholzab  et al. 1991), although in Deneson’s fore mentioned cohort this figure was as 
high as  34%. Most patients  present as a UC relapse or as a complication of corticosteroid 
dependence (Macken  & Blako. 2015). Multiple indices used to assess disease severity have 
been published. However Truelove and Witt’s criteria remain the corner stone of identifying 
ASUC, especially in daily clinical practice. Laboratory markers have been studied 
extensively with varying degrees of success. The widely used acute phase reactant CRP is 
inferior in assessing disease activity in UC when compared to  Crohn's disease, except for 
ASUC, where it has established value in both adults and children (Dignass et al. 2012). 
Among objective clinical features, bloody stool frequency, increased body temperature and 
tachycardia are good predictors of severity and outcome. Radiological findings which include 
Megacolon (colon dilatation of > 5.5 cm), an ahaustral lining, thumb printing (suggestive of 
mucosal oedema) and features of a small bowel ileus are predictors of severity in UC (Chew 
et al. 1991). Megacolon and mucosal islands on plain radiographic films have been described 
as predictors of colectomy in ASUC with 75% risk of colectomy (Lennard-Jones et al. 1975). 
The Modified Mayo Score is used more frequently in clinical trials and it includes stool 
frequency, rectal bleeding, endoscopy findings and Physicians global assessment. The 
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maximum Mayo score assessment index is 12. Clinical response is defined as a decrease of at 
least 3 points and at least a 30% decrease from the baseline Mayo score, accompanied by a 
rectal bleeding sub-score decrease of at least 1 point and an absolute rectal bleeding sub-score 
of 0 or 1. Clinical remission as a Mayo score of 2 or less and no sub-score more than 1; and 
mucosal healing as an absolute Mayo endoscopy sub-score of 0 or 1 (Côté-Daigneault et 
al.2015). The Second European evidence based consensus (ECCO) acknowledges the 
importance of microscopic findings at endoscopy ( chronic inflammatory cell infiltrate, crypt 
abscesses, mucin depletion and branches in the surface epithelium) as predictors of severity 
in patients recurrent of UC  relapses (Dignass et al. 2012). 
MEDICAL MANAGEMENT OF ASUC 
Acute severe ulcerative colitis should be approached as a medical emergency. Prompt 
evaluation of ASUC patients is mandatory, laboratory studies including a full blood count,  
liver function testing, inflammatory markers (CRP,ESR), renal function testing, electrolytes 
(calcium, magnesium and phosphate), albumin levels and  stool studies to rule out infectious 
causes especially Clostridium difficle are required. In addition it is prudent to perform a 
limited evaluation of the colon with flexible sigmoidoscopy to confirm the presence, severity 
and extent of the inflammation and also to take biopsies for confirmation of UC and 
exclusion of cytomegalovirus infection (which frequently complicates ASUC). Full 
colonoscopy should be avoided as it can precipitate toxic megacolon and increases the risk of 
perforation. Plain abdominal and chest radiography at presentation is mandatory as it helps to 
determine the extent of disease, will detect the presence of megacolon, thumb printing and 
mucosal islands and pick up other pathologies like pulmonary infections and bowel 
perforation. Bowel rest is not recommended in patients with ASUC. Although it might help 
reduce stool volume, there is no established benefit in terms of disease activity (Mcintyre et 
al. 1986). Nutritional support is recommended in patients who are malnourished. Enteral 
nutrition is preferred as it has shown benefit in the metabolism and repair of the colon 
epithelial cells form short chain fatty acids when compared to parenteral nutrition which 
deprives the colon of short chain fatty acids (González-Huix et al. 1993). ASUC patients 
should always receive thrombotic prophylaxis with standard doses of heparin as there is 
evidence of a prothrombotic state during this period (Grainge et al. 2010).  
Although ASUC is difficult to distinguish from infective colitis; treatment should not be 
delayed until stool microbiology results or histology is available. It may be appropriate to 
commence both corticosteroids and antibiotics (Mowat et al. 2011). Geographic area 
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determines the standard practice in terms of using empiric antimicrobials. The routine use of 
intravenous antibiotics in patients with uncomplicated ASUC is not recommended, although 
it may be appropriate when incipient colonic perforation, toxic dilatation or infection is 
suspected  (Mantzaris et al. 2001). Any medications that can precipitate colonic dilatation, 
including opiates, NSAIDs, anti-cholinergics and anti-diarrhoeas, should be avoided (Macken 
& Blaker.  2015). 
Corticosteroids remain the mainstay medical treatment of ASUC and will induce remission in 
the majority (70%) of cases. Corticosteroids are given intravenously, usually at high doses 
(Turner et al. 2007). Most patients will respond to intravenous steroid therapy and may be 
switched to oral prednisolone 1mg/kg (40-60 mg daily with tapering down over the next 2-3 
months). Response to steroids is indicated by improvement in patients’ symptoms decreased 
stool frequency, urgency and rectal bleeding, improved stool consistency, reduction in 
abdominal pain, and improvement in general well-being and improved laboratory parameters 
(reduced CRP and improvement in haemoglobin and albumin). Intensive inpatient treatment 
with intravenous corticosteroids and early surgical intervention has reduced the UK mortality 
from ASUC to 2.9% (Arnott I et al. 2009). 
  
CORTICOSTEROID FAILURE IN ASUC 
Although most patients with severe UC respond to intravenous steroid therapy, 
approximately 30% of patients fail to respond after 5-7 days and are termed steroid refractory  
(Turner et al. 2007). Corticosteroid failure is an indication for either medical rescue therapy 
or emergency colectomy. Severe steroid side effects like Psychosis, Osteoporosis, and 
bleeding peptic ulcer are also an indication for medical rescue therapy. Response to 
intravenous corticosteroids should be assessed early. It is important to identify failures 
timeously as there is a small window of opportunity to save the colon. Objective markers of 
steroid failure should be used to diagnose steroid refractory ASUC. Clinical markers that 
suggest corticosteroid refractoriness include the passage of  >4 stools per day with blood after 
3 days of intravenous glucocorticoid therapy (Lindgren et al. 1998); in patients not 
responding after 3 days the immediate risk of colectomy rises to 85%  (Travis et al. 1996).  
In addition to assessing UC severity there are other criteria that are used to identify 
corticosteroid failure in patients receiving this therapy for ASUC. Travis et al suggested in 
their prospective study that a stool frequency of > 8/d or 3-8/d and C-reactive protein (CRP) 
> 45 mg/dL on the third day of corticosteroid therapy is sufficient evidence of corticosteroid 
failure and should prompt  rescue therapy. These  criteria known as the Oxford Index are still 
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clinically relevant and widely used (Travis et al. 1996). Lindgren subsequently described the 
fulminant colitis index to identify early those patients that are steroid refractory and would 
need rescue therapy (Lindgren et al. 1998). The fulminant colitis index was calculated on day 
3 after the initiation of IV steroids according to the following formula: number of bowel 
movements ⁄ day + (0.14 x CRP> 8mg⁄ L), Seventy-two percent of patients with a value > 8.0 
required a colectomy. The Seo index includes variables calculated from the preceding day 
(day 2 of corticosteroid therapy) and is derived from the following formula: 60 x blood in 
faeces + 13 x bowel movements ⁄ day + 0.5 x ESR - 0.4 x Hb (g ⁄ l) - 1.5 x albumin (g ⁄ l) + 
200. Constants are as follows:  for blood in faeces 0 indicates none and 1 indicates present; 
for bowel movements 0 indicates 0–3 stools per day; 1 indicated 4 stools per day ; 2 indicated 
5–7; and 3 indicated > 8. A value < 150 – 220 corresponds with remission or mild UC, 150–
220 corresponds with moderately severe UC, and > 220 corresponds with severe UC (Seo et 
al. 1992). Ho proposed the Scottish Index based on stool frequency, presence of colonic 
dilatation, and hypoalbuminemia (Ho et al. 2004). In children the Paediatric UC Activity 
Index (PUCAI) score on days three and five of steroid therapy has been validated as a 
predictor of initiating rescue therapy (Randal et al.2010; Turner et al.2010).  
 
MEDICAL RESCUE THERAPY 
Two main agents are used as rescue therapy in ASUC; infliximab and cyclosporine. 
Infliximab is a chimeric IgG-1 monoclonal antibody that specifically targets free and 
membrane-bound tumour necrosis factor-alpha.  Infliximab is the only biologic that has 
proven efficacy in management of ASUC as an induction and maintenance therapy (Côté-
Daigneault et al. 2015). Cyclosporine is the second option in steroid refractory ASUC. It is an 
inhibitor of the transcription factor NFK-β of activated T cells and attenuates the production 
of interleukin-2 from these cells. There is no definite preference on which of these 2 salvage 
therapies to use as they have advantages and disadvantages depending on the patients clinical 
status and physician`s preference.  
The GETAID study found that infliximab was not inferior to cyclosporine as a rescue 
treatment to avoid colectomy (Laharie et al. 2012). They documented clinical response rates 
for cyclosporine of 84% (2mg/kg IV daily dose for 1 week) and Infliximab clinical response 
rates of 84% (5mg/kg as a single dose). Treatment failure rates were also competitive at day 
90 (60% for cyclosporine and 54% for Infliximab). Azathioprine was initiated on day 7 in 
those patients that showed a clinical response. Early results from another  randomised 
controlled trial (CONSTRUCT) comparing cyclosporine with infliximab also suggests that 
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there is  no significant difference in quality adjusted survival, colectomy rates, mortality and 
serious adverse reactions between the two treatments (Seagrove et al. 2014).  
 Jarnerot et al showed that infliximab was significantly  better than placebo in his small study 
of patients with ASUC: more patients in the placebo group (14/21) than in the infliximab 
group (7/24) had a colectomy; this difference was statistically significant ( P < 0.017) with an 
odds ratio (OR) of 4.9 (95% confidence interval [CI], 1.4–17) in favour of infliximab 
(Jarnerot et al. 2005). 
Cyclosporine  as a rescue therapy is also supported  by the ECCO consensus (Dignass, et al. 
2012). Cyclosporine has shown proven efficacy in ASUC since 1994 with response rate of 64 
to 84 %. It has a rapid onset of action and allows timely intervention to prevent colectomy in 
non-responders. Its clinical efficacy whilst proven, comes with risks of toxicity including 
nephrotoxicity, hypertension, seizures/ neurotoxicity. Its short term value as rescue therapy 
should be balanced by the longer term colectomy rates seen despite its use (88% colectomy 
rate at seven years), and high rates of colectomy in patients previously exposed to thiopurines 
(Eun & Hand.2015). Sequential use of calcineurin inhibitors followed by infliximab or vice 
versa may be successful in approximately 25%-40% of adult patients, but is associated with 
significant morbidity and even mortality (Dayan & Turner. 2012). Other biologicals like 
adalimumab, certolizumab and golimumab have no clinical trials published as treatment 
options for ASUC. The ultimate management of ASUC is colectomy when medical rescue 
therapy fails. 
 
COLECTOMY IN ASUC 
Clinical parameters which have been studied as predictors of colectomy in ASUC include a 
stool frequency of more than 12 per day on day 2, which conferred a 55% rate of colectomy 
in a retrospective study of 166 patients (Lennard-Jones et al. 1975), while stool frequency 
greater than 8 per day on day 3 was associated with a 85% colectomy rate in another 
prospective study of 55 admissions (Travis et al. 1996). Disease extent is also an important 
predictor of colectomy; patients with extensive colitis have a four-fold increased risk when 
compared to those who have proctitis alone.(Solberg et al. 2009). Extensive deep ulceration 
on endoscopy is a very strong predictor with a 93% risk of colectomy (Daperno et al. 2004). 
Serum albumin may also be a useful predictor in that in a retrospective study of 189 
admissions colectomy was required in 42% of patients with a serum albumin< 30 g/L 
(Lennard-Jones et al. 1975; Ho et al.2004). However albumin as an independent predictor of 
colectomy showed less convincing results in other prospective studies (Travis et al. 
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1996;Turner et al.2010). Toxic megacolon (which is defined as colonic dilatation of ≥ 6cm or 
caecal diameter> 9 cm, with systemic symptoms) and mucosal islands on plain abdominal X-
ray have been described as predictors of colectomy in ASUC with a 75% risk of colectomy.  
Indications for colectomy in ASUC include non-response to medical rescue therapy 
(especially patients with prior exposure to thiopurines or biologicals),toxic megacolon and 
severe bleeding (Sandborn et al. 2009; Nicholls et al.2002). The exact timing of surgery is 
still debatable; application of the standard IBD multidisciplinary team (MDT) 
recommendations (based on a study that was conducted in 2 UK regions) attempts to ensure 
quality of care and consensus with regard to decision making (Morar et al. 2014). Early 
surgical intervention removes the source of inflammation that drives the illness, leading to 
decreased morbidity associated with prolonged steroid use and rescue therapy. However 
surgery comes with its own complications which include wound sepsis and dehiscence, stoma 
failure, dehydration and hygiene challenges related to the stoma effluent. 
Colectomy is indicated from 4-7 days after rescue therapy in non-responders. Prolonged 
medical therapy in refractory systemic ill patients results in poor outcomes if surgery is 
instituted. The recommended operation in ASUC is subtotal colectomy and end-ileostomy, 
with the rectum left in situ as a non-functioning Hartmann’s pouch or occasionally as a 
mucus fistula, reconstruction is not an option in the acute setting (Arnott I et al. 2010). 
Laparoscopic colectomy when performed in large volume centres has less morbidity than an 
open operation.  Patients are allowed to fully recover from the surgery and learn to manage 
and cope with their ileostomy. Several options are available for restoration of bowel 
continuity. They are dependent on how severely the rectum is involved, the strength of the 
anal sphincter and the patient’s circumstances and preference. A completion proctectomy 
with ileal pouch anal anastomosis in those who have completed their family is what the 
majority will opt for. An ileorectal anastomosis spares the risk of sexual dysfunction due to a 
proctectomy and is the preferred option for those who wish to procreate. In those with poor 
sphincter control they will be best served by a proctectomy and remain with their ileostomy. 
This staged approach with a minimally invasive completion protectomy and ileal pouch-anal 
anastomosis resulted in no mortality and only one anastomotic leak in a series of 50 patients 
(Holubar et al. 2009). Delayed surgery in patients with prolonged in-hospital medical 
treatment (8 versus 5 days; P =0.036) was the only factor associated with increased post-






Ulcerative colitis is a complex chronic autoimmune inflammatory disease of variable 
severity. ASUC is a potentially fatal condition with an associated mortality ranging from 
2.9% in peripheral centres to less than 1% in specialist inflammatory bowel disease centres. It 
has well defined diagnostic criteria, severity assessment parameters and treatment algorithms 
based on clinical response. The medical treatment, directed by a consultant gastroenterologist 
in close liaison with a colorectal surgeon, aims to allow the patients to recover from the acute 
systemic response and avoid an emergency colectomy with its high morbidity. These 
management pathways and outcomes are derived from data obtained in developed countries. 
There are no recent reports on ASUC behaviour, therapy and outcomes in patients from our 
region and in particular if multiple indices used to predict colectomy elsewhere are applicable 
to our patients. 
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INTRODUCTION: Acute Severe Ulcerative Colitis (ASUC) is a life threatening condition 
which requires urgent and aggressive medical therapy to reduce mortality, morbidity and 
avoid surgery. To facilitate this process it is essential to identify patients at high risk of poor 
outcomes and emergency colectomy. Numerous such risk factors have described in the 
Western literature however there are no local data addressing this issue. As such it is unclear 
if these predictors are applicable in our setting. The aim of this study is thus to identify risk 
factors for emergency colectomy in patients admitted to Groote Schuur Hospital with ASUC.   
METHODS: A retrospective cohort study of 98 patients admitted with ASUC between 
January 2003 and January 2013 was performed. Clinical, demographic, laboratory and 
endoscopic factors on admission and 3 days thereafter were analysed as predictors of 
colectomy by univariate and multivariate analysis. 
RESULTS: Twenty five percent of the cohort underwent emergency colectomy. On 
univariate analysis factors predicting colectomy on admission were exposure to oral 
corticosteroids (p=0.01), megacolon (p=0.049) or mucosal islands (p=0.04) on abdominal X-
ray, and a short duration from UC diagnosis until presentation with ASUC (p=0.04). The only 
variable that was significantly associated with colectomy on day 3 was serum albumin 
(p=0.01). This was also the only variable to remain significant on multivariate analysis (OR 
0.79, 95% CI 0.65-0.97, p=0.01).  
30 
CONCLUSION: ASUC is a medical emergency and predicting colectomy risk aids in 
therapeutic management. The only variable significantly associated with the need for surgery 
in our study was hypoalbuminaemia on day 3. Given the small study numbers a larger 
prospective study would be of value. 
INTRODUCTION 
Ulcerative colitis (UC) is the most common form of Inflammatory Bowel Disease (IBD). It is 
characterised by a relapsing and remitting course. Most episodes of active UC are mild to 
moderate in severity and can be managed as outpatients, however about 15% will have an 
acute severe flare of their disease in their life time, requiring admission.[1] Acute severe UC 
(ASUC) is best defined using Truelove and Witts criteria by the presence of > 6 bloody stools 
per day with any of the following 4 criteria: a tachycardia (>90 bpm), fever (>37.8c), anaemia 
(haemoglobin <10.5 g/dl), or an elevated erythrocyte sedimentation rate (ESR) or CRP (>30 
mm/h) (Appendix 1).[2] ASUC is a medical emergency which carries a high risk of 
colectomy. Fortunately the majority of cases respond rapidly to intravenous corticosteroids, 
which were first used as therapy in 1955. This simple intervention together with correction of 
fluid and electrolyte abnormalities, treatment of concurrent infections, close monitoring by a 
multidisciplinary team and timely colectomy has significantly reduced mortality rates to less 
than 1% in specialist units. [3]  
In order to optimise management of this life threatening condition it is important to identify 
patients at presentation who will be at high risk of complications and may require colectomy; 
these individuals would then receive urgent and aggressive therapy with intravenous 
corticosteroids. Multiple predictors of severity in ASUC have been described. These include 
stool frequency, fever, tachycardia, disease extent, young age, serum albumin, haemoglobin, 
C-reactive protein (CRP), and extensive deep ulceration on endoscopy.[3-6]  In addition
megacolon and mucosal islands on plain abdominal X-ray have been described as predictors
of colectomy in ASUC, conferring a 75% risk of surgery. [4] Unfortunately 30% of patients
will not respond to corticosteroids and it is essential to identify these patients early so as not
to prolong ineffective therapy but rather initiate salvage therapies in the form of cyclosporine
or infliximab, or alternatively perform colectomy. [5] Several scoring systems have been
proposed to identify corticosteroid failures; the one most commonly used is the Oxford Index,
whereby a stool frequency exceeding 8/day or 3-8/day plus a CRP > 45 mg/dL on the third




The fore mentioned predictors of colectomy (on admission and on day 3 of corticosteroid 
therapy) have been identified from cohorts in other regions of the world, mostly USA and 
Europe. There is no data from South Africa and it is thus unclear whether they are of value in 
our population.  
 
The aim of this study is thus to evaluate the role of these predictors of emergency colectomy 
in our IBD cohort and reflect on outcomes of ASUC in our setting. Limitation of access to 
rescue therapy (biologics) in our setting has prompted us to identify these predictors so as to 
minimize prolonged ineffective inpatient medical therapy and reduce the economic constraint 
associated with delayed colectomy complications. 
 
METHODS 
A retrospective review of folders of all patients admitted to Groote Schuur Hospital, (Cape 
Town, South Africa) with a diagnosis of ASUC. The study period was from the 01 January 
2003 to 31 December 2013. This study received approval from the UCT Human Research 
Ethics Committee (Appendix 2). 
 
Definitions: 
ASUC was defined using the Truelove and Witts criteria: that is frequency of six or more 
bloody stools per day together with any one of the following criteria: 
 Tachycardia (>90 bpm) 
 Temperature greater than 37.8°C 
 Anaemia (haemoglobin <10.5 g/dL) 
 An elevated ESR (>30 mm/h) or CRP (>30) 
Corticosteroid failure was defined on day 3 of intravenous steroids by the presence of either 
of the following Oxford Index criteria: 
 Stool frequency exceeding 8 stools per day 
 3 - 8 stools per day together with a CRP > 45  
Inclusion criteria for the study:  
 Patients admitted with a clinical diagnosis of ASUC satisfying Truelove and Witts 
criteria (Appendix 1). 
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 Patients who had undergone a colectomy with a confirmed clinical and histological 
diagnosis of ASUC. Patients with a revised secondary diagnosis within ninety days 
were excluded.  
Patients were identified from inpatient admission records, surgical files, as well as an 
established IBD database. All patients admitted to a medical ward were treated with 
intravenous corticosteroids at standard doses.  
Data collected included baseline demographics (age, gender, family history, ethnicity, 
smoking status, duration of UC prior to ASUC diagnosis, time from diagnosis to 
presentation, and medication exposure on admission). Clinical, biochemical, laboratory 
variables, radiological and sigmoidoscopy findings on admission and on day 3 of intravenous 
corticosteroids were also extracted, as were indications for colectomy and 90 day outcomes. 
Outcome measures assessed were death within 90 days of presentation, colectomy free 
survival at 90 days and surgical complications 
 
STATISTICAL ANALYSIS 
The distribution of all continuous variables was evaluated and expressed as medians and 
interquartile ranges (IQRs) or means ± standard deviations (SD) as appropriate. Statistical 
analysis employed Chi2, Fishers exact, Student t test, Wilcoxon rank sum test or Kruskal-
Wallis testing as appropriate. Those variables with P values below 0.10 were further tested in 
a series of logistic multivariate regression models. The analysis was performed using STATA 
version 11 (StataCorp. 2009. Stata Statistical Software: Release 11. College Station, TX: 
StataCorp LP). This study was approved by the Ethics Committee of the University of Cape 
Town (Appendix 3) 
 
RESULTS 
Ninety eight patients with ASUC were eligible for study inclusion. Sixty four percent were 
female. The mean age at first diagnosis of UC was 39 years and the mean age at the time of 
the ASUC flare was 43 years; only 47% were older than 40 years of age at the time of the 
attack. The mean duration between diagnosis and admission for ASUC was 61 months. For 
17% this was the first presentation of their disease. All the patients had extensive colitis 
(Appendix 1) with deep ulceration (figure 1). Forty one percent of the cohort were Caucasian, 
37% Coloured, 11% Asian and 11% Black. With regards to medication use at the time of 
admission: 76% were using 5-aminosalicylates (5-ASAs) and 26% thiopurines, none were 
receiving maintenance biologics. Only 5% of patients had a positive family history of IBD. 
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Overall 47% were non-smokers. These baseline demographics are presented in table 1.On 
initial work up only 1 patient (who did not require colectomy) had concurrent Clostridium 
difficle infection and was treated with metronidazole with good effect. No cases of 
cytomegalovirus were detected.  
 
Twenty five of the 98 patients (25%) underwent a colectomy during the study period, 64% 
were female which was similar to patients who did not require surgery (Table 2). Eighty 
percent of patients had their emergency colectomy within 15 days of admission; only half of 
these were operated on within 7 days. 38% of patients had complications within 90 days post 
admission which included sepsis (pneumonia, wound sepsis). There were no deaths within 
the 90 day follow up. 
Of patients undergoing colectomy 52% were of Caucasian ethnicity, 40% were Coloured, and 
8% Asian. None of the black patients required surgery. There was no significant association 
between colectomy and ethnicity. The mean age of patients at colectomy was 39 years which 
was not significantly different from those who did not require colectomy. The group of 
patients undergoing surgery for ASUC had a significantly shorter duration of disease than 
those in whom colectomy was avoided; 16 months and 41 months respectively (p=0.04) 
On univariate analysis non-smoking status was not associated with an increased risk of 
colectomy, nor was a positive family history of IBD or exposure to 5-ASAs or thiopurines 
(Table 2). In contrast patients requiring colectomy were significantly more likely to have 
received treatment with oral corticosteroids than those who avoided surgery (p=0.01). None 
of the patients were on maintenance Infliximab at the time of ASUC admission, however 4 
patients received Infliximab as rescue therapy and all of them avoided colectomy. On 
univariate analysis there was no significant difference with regards to any of the baseline 
laboratory or clinical variables (median number of stools per day, body temperature, 
haemoglobin, serum albumin, or CRP) when comparing patients requiring colectomy with 
those who did not (Table 3). In contrast radiologic evidence of megacolon or mucosal islands 
on abdominal X-ray were significantly more likely to be present in subjects requiring surgery 
than in those who did not (32% and 40% respectively)  
Analysis of day 3 data showed that serum albumin was significantly associated with the need 
for colectomy (p=0.01). In contrast all the other variables analysed at this time point 
(haemoglobin, temperature, and CRP) did not correlate significantly with the risk of 
colectomy (Table 4). Furthermore patients meeting the Oxford Index criteria for 
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corticosteroid failure on day 3 were no more likely to require colectomy than those who did 
not.  
On multivariate logistic regression only serum albumin on day 3 was significantly associated 
with colectomy (OR 0.79, 95% CI 0.65-0.97, p=0.003) 
 
DISCUSSION 
Acute severe ulcerative colitis is a medical emergency because of the risk of colonic 
perforation; prompt recognition and timely medical or surgical intervention within the setting 
of a multidisciplinary team is crucial to reduce morbidity and mortality. [1] In order to 
optimise care and facilitate aggressive management strategies there is an urgent need to 
identify patients at very high risk for colectomy. As a consequence the role of prognostic 
factors in patients with ASUC has been the subject of much interest.  
Multiple predictors of severity have been described. Among objective clinical features, 
bloody stool frequency, increased body temperature and tachycardia are good predictors of 
severity and outcome.[1] In a retrospective study of 166 patients a stool frequency of more 
than 12 per day conferred a 55% risk of colectomy.[2] Laboratory markers have also been 
studied extensively with varying degrees of success. The widely used acute phase reactant 
CRP has established value in ASUC in both adults and children. [1] Serum albumin may also 
be predictive; in a retrospective study of 189 admissions hypoalbuminemia (serum albumin 
less than 30 g/L) on the first day of admission was associated with a 42% risk of colectomy. 
[4] However results from multiple prospective studies have shown less convincing results. 
Radiological findings which include megacolon (colon dilatation of > 5.5 cm), thumb 
printing (suggestive of mucosal oedema), the presence of mucosal islands and features of a 
small bowel ileus are also predictors of severity in UC. [2] Megacolon and mucosal islands on 
plain abdominal X-ray have been shown to confer a 75% risk of colectomy. [4] Disease extent 
is also an important predictor of the need for surgical intervention; patients with extensive 
colitis have a risk 4 times higher than those with limited UC. Deep ulceration on endoscopy 
is also an ominous sign in ASUC; 93% will require surgery. [6,7] Patients who present with a 
disease flare and any of these risk factors require immediate admission and urgent 
intervention.  
 
Intravenous corticosteroids are the mainstay of therapy. Unfortunately 30% of patients will 
fail to respond to corticosteroids and it is essential to identify these patients early so as not to 
prolong ineffective therapy but rather initiate salvage therapies in the form of cyclosporine or 
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infliximab, or alternatively perform colectomy. [2] Colectomy is a lifesaving intervention and 
the ability to predict the need for surgery and its timing is key in decreasing morbidity and 
surgical complications.  
Response to steroids should be assessed at day 3 of admission and partial or non-responders 
considered for rescue medical therapy or surgery. Several scoring systems have been 
proposed to identify corticosteroid failures; the one most commonly used is the Oxford Index, 
whereby a stool frequency exceeding 8/day or 3-8/day plus a CRP > 45 mg/dL on the third 
day of corticosteroid therapy is considered sufficient evidence of corticosteroid failure and 
should prompt rescue therapy. [2] Colectomy is indicated from 4-7 days after rescue therapy 
in non-responders. Prolonged medical therapy in refractory systemic ill patients results in 
poor outcomes if surgery is delayed. [8]  
Our study evaluated all of these fore mentioned risk factors and has identified several which 
significantly predict colectomy during admission for ASUC. Firstly a shorter duration of 
disease conferred a higher risk of subsequent surgery than patients with a longer duration of 
disease. This is in keeping with other publications which show that most severe attacks of UC 
occur within 3 months of diagnosis. [6] In our study the use of thiopurines and 5-ASAs did not 
impact on colectomy rates. In contrast (and not surprisingly) patients who were already on 
oral steroids on admission were more likely to undergo colectomy. This has been described 
previously and oral corticosteroids are a well described risk factor for colectomy in ASUC. [9] 
It is common practise in our institution to admit patients who have failed to respond to oral 
steroids and give them a trial of intravenous therapy. These individuals likely have more 
severe UC and have already shown themselves to be (at least partially) steroid refractory. As 
such they would inherently be at greater risk of needing emergency surgery. [9,10] All other 
baseline demographics were not significantly associated with the risk of colectomy. 
Interestingly most of the ASUC patients were female. This is not in keeping with 
international literature which reports a male predominance; with a male to female ratio of 
36:16. [10-11] Of interest is the 0% colectomy rate in the black population; this likely reflects 
the small numbers included but merits further evaluation. With regards to baseline laboratory 
investigations, none were shown to increase the risk of colectomy. This is at odds with what 
is reported in the literature where the risk of colectomy increases as more Truelove and Witts 
criteria are fulfilled. [13] As such it appears logical that baseline haemoglobin and CRP levels 
would be of value. Similarly a low serum albumin on presentation is a well described 
predictor of the need for surgery.[14] Serum albumin levels on admission did not predict 
colectomy in our study however hypoalbuminaemia on day 3 was significantly associated 
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with an increased need for surgery. This was the only variable that remained statistically 
significant on multivariate analysis and likely reflects ongoing, severe inflammation which 
has failed to respond to corticosteroids and which should prompt escalation of therapy. 
 
There are some other interesting observations which have emerged from this study. The 1st is 
the 100% success rate of infliximab in patients failing corticosteroids. Although numbers 
were small this suggests that appropriate patients are being selected. Another observation 
which is somewhat disturbing is that 40% of patients had their colectomy between 8 and 15 
days of admission. It is unclear why surgery was delayed in these individual but this could 
explain the high incidence of post- operative complications. It is well described in the 
literature that delaying surgery is associated with higher morbidity and mortality in ASUC.[8]  
 
This study has several weaknesses, mostly as a consequence of its retrospective design. Due 
to inconsistent documentation of admission data in both medical and surgical wards, it is 
likely that some cases of ASUC would have been overlooked. However this data is likely 
missing at random and should not impact study results to any great extent. This is supported 
by our colectomy rate of 25 % which is in keeping with that reported in the world literature. 
[15] A second study weakness is the relatively small numbers of study subjects. This could 
have led to a Type 11 error which could explain the lack of significance of many of the 
variables analysed on presentation and on day 3 (notably the Oxford index of severity). A 





ASUC is a medical emergency, predicting which patients will likely require colectomy is a 
very valuable tool in guiding therapeutic management. In our study the only variable 
significantly associated with colectomy was hypoalbuminaemia on day 3. However given the 
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Table 1: Baseline demographic and clinical parameters of patients with ASUC  
 
Variable  Value  
Gender 




Median age at UC diagnosis in years  
 
38 (27 – 52) 
Mean age at ASUC flare diagnosis in years 
 
43.2 + 15.48 
Median duration of disease from UC to ASUC diagnosis in months 
 
30 (6 -106) 
Race 
    Caucasian 
    Coloured 
    Black 







Medication exposure prior ASUC 
    5 ASA 
    Thiopurines 
    Oral steriods 





    Non-smoking status 
 
46 (47%) 




    Median albumin day 1® 
 
34 (22 - 41) 
    Median haemoglobin day 1® 12 (10.8 – 13.2) 
    Median C reactive protein day 1® 53  (17 – 130.1) 
    Median number o of stools day 1® 8 (6 - 10) 
    Median  ESR® 47 (32 – 68) 
    Median temperature ® 36.8 (36 – 37.2) 
 ASA = Aminosalicylate. Continuous variables are recorded as medians (IQR, 25% - 75%) or mean.± SD. 

















First presentation of UC 7 (28%) 10 (14%) 
 
0.50 
Mean age at UC diagnosis (years) 39.16+ 16.26 
 
38.78 + 15.66 
 
0.92 
Mean age  at ASUC presentation (years) 42 + 17.1 
 
 




>40 years of age at ASUC presentation 
 
14 (56%) 32 (44%) 0.18 
 
Median duration in months from UC 
diagnosis to ASUC diagnosis 
 
16 (1 – 56) 41 (7.5 – 111) 0.04 
Gender :female  16 (64%) 45 (62%) 0.83 
 
Ethnicity 
    Caucasians 
    Coloureds 
    Blacks 











9   (12%) 
 
0.15 
Family history of UC 













Medication prior ASUC 
    5 ASA 
    Thiopurines 




7   (28%) 









UC = Ulcerative Colitis; ASUC = Acute Severe Ulcerative Colitis; * All continuous variables are recorded as 









 (n =73) 
P value  
Median number of stools per day 8 (6 -10) 8 (6 – 10) 0.24 
Median Temperature 36.8 (36 – 73.5) 36.8 (36.1 – 37.2) 0.76 
Median Haemoglobin 12.2 (11.2 – 13.3) 11.6 (10.1 – 12.8) 0.24 
Median CRP 48.3 (15.5 – 156) 53.2 (16.3 – 118.2) 0.10 
Median serum Albumin 36.4 (33 – 40.6) 37 (33 – 42) 0.51 
Radiology findings 
     Megacolon 







   All continuous variables are recorded as medians (IQR, 25% - 75%). CRP = C reactive protein. 
Table 4: Factors predicting colectomy on day 3 of intravenous steroids 
Variable Colectomy 
 (n  -25) 
No colectomy 
 (n - 73) 
P value  
Median number of stools per day 4 (2-6) 3 (2-4) 0.21 
Median temperature 36.15 (36-36.8) 36 (36.5) 0.15 
Median Haemoglobin 10.8 (9.5-11.6) 10.6 (9.9-11.8) 0.81 
Median CRP 55 (19-103) 27 (10.5-50.5) 0.10 
Median albumin 26 (25-32) 34 (30-36) 0.01 
Patients meeting the oxford Index Criteria 4/19 (21%) 9/70 12.9%) 0.46 
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Appendix 1 
Montreal classification of Ulcerative colitis 
Montreal classification of extent of Ulcerative colitis (UC) 
Extent Anatomy 
E1      Ulcerative proctitis Involvement limited to the rectum (that is, 
proximal extent of inflammation is distal to 
the rectosigmoid junction) 
E2      Left sided UC (distal UC) Involvement limited to a proportion of the 
colorectum distal to the splenic flexure  
E3      Extensive UC (pancolitis) Involvement extends proximal to the splenic 
flexure 
 Montreal classification of severity of Ulcerative Colitis (UC) 
Severity Definition 
S0      Clinical remission Asymptomatic 
S1      Mild UC Passage of four or fewer stools/day (with or 
without blood), absence of any systemic 
illness, and normal inflammatory markers 
(ESR) 
S2     Moderate UC Passage of more than four stools per day but 
with minimal signs of systemic toxicity   
S3     Severe UC Passage of at least six bloody stools daily, 
pulse rate of at least 90 beats per minute, 
temperature of at least 37.5°C, haemoglobin 
of less than 10.5 g/100 ml and ESR of at least 
30 mm/hr.  
ESR = Erythrocyte sedimentation rate 
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